- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01699750
Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems
December 3, 2014 updated by: Alcon Research
The purpose of this study is to evaluate the lipid uptake, wetting characteristics, and visual performance of AIR OPTIX® AQUA and ACUVUE® OASYS® with HYDRACLEAR® contact lenses when used in conjunction with two contact lens care systems.
Study Overview
Status
Completed
Conditions
Detailed Description
This study will be divided into two phases.
In the Pre-Investigational Phase (Phase 1), participants will wear PureVision contact lenses for 30 days and use ReNu® Multiplus® for contact lens care.
Eligible participants will continue into the Investigational Phase (Phase 2) and be randomly assigned to wear AIR OPTIX® AQUA contact lenses or ACUVUE® OASYS® with HYDRACLEAR® contact lenses for a total of two months.
For contact lens care, participants will use OPTI-FREE® PUREMOIST® MPDS and BIOTRUE® for 30 days each.
Study Type
Interventional
Enrollment (Actual)
109
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Fort Worth, Texas, United States, 76134
- Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Read and understand the Participant Information Sheet;
- Read, sign, and date the Informed Consent;
- Be a current silicone hydrogel contact lens wearer using the contact lenses under a frequent replacement (bi-weekly or monthly) daily wear modality;
- Be classified as symptomatic and a depositor at the end of the replacement period according to protocol-specified criteria;
- Agree to wear study contact lenses as directed for the duration of the study and maintain the appointment schedule;
- Best corrected visual acuity of 6/9 or better in each eye;
- Normal eyes with the exception of the need for visual correction;
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Known sensitivity or intolerance to any of the contact lenses or contact lens care products to be used;
- Monocular vision (only one eye with functional vision or only one eye fitted with contact lenses);
- Use of systemic medication which might interfere with contact lens wear or produce dry eye side effects;
- Systemic disease which might interfere with contact lens wear or produce dry eye side effects;
- Systemic or ocular allergies which might interfere with contact lens wear;
- Ocular disease which might interfere with contact lens wear;
- Active ocular infection;
- Use of any concomitant topical ocular medications during the study period;
- Previous ocular surgery;
- Pregnant, planning to become pregnant, or lactating at the time of enrollment;
- Participation in an investigational drug or device study within 30 days of entering this study;
- Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Air Optix Aqua
Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
|
Silicone hydrogel contact lenses, Phase 2
Other Names:
Contact lens care system, Phase 2
Other Names:
Contact lens care system, Phase 2
Silicone hydrogel contact lenses worn for 30 days, Phase 1
Other Names:
Contact lens care system used for 30 days, Phase 1
|
Active Comparator: Acuvue Oasys
Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
|
Contact lens care system, Phase 2
Other Names:
Contact lens care system, Phase 2
Silicone hydrogel contact lenses worn for 30 days, Phase 1
Other Names:
Contact lens care system used for 30 days, Phase 1
Silicone hydrogel contact lenses, Phase 2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Ex-Vivo Total Lipid Uptake Per Lens
Time Frame: Day 30
|
The contact lens was aseptically removed from the eye.
Lipids were extracted and analyzed using a proprietary High Performance Liquid Chromatography technique.
A lower value indicates a cleaner lens surface.
One eye (study eye) contributed to the mean.
|
Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Non-Invasive Pre-Lens Tear Film Break Up Time (NIBUT)
Time Frame: Day 30
|
The pre-lens tear film is the layer of tears located on top of the contact lens between the eyelid and the contact lens.
NIBUT (i.e., the time elapsed between eye opening after a blink and the appearance of the first dark spot within the tear film) was measured using a diffuse illumination source (Tearscope) and videotography.
A longer NIBUT indicates a more stable tear film and greater on-eye lens wettability.
One eye (study eye) contributed to the mean.
|
Day 30
|
LogMAR Time-Controlled Visual Acuity (TCVA)
Time Frame: Day 30
|
Visual performance was measured binocularly (both eyes together) at two contrast levels using a validated Time Controlled Visual Acuity test (TCVA).
TCVA was recorded in VA units (1 VA unit=1 VA line=0.1 logMAR), with positive (+) values corresponding with VA better than 20/20 and negative (-) values worse than 20/20.
|
Day 30
|
Overall Comfort Measured With Visual Analog Scale (VAS)
Time Frame: Day 30
|
The participant rated overall comfort on a 100-millimeter analog scale by marking a line that best corresponds to their eye comfort (0=very poor, 100=excellent).
Both eyes were rated together as a single, retrospective evaluation of the previous 3 days of wear.
|
Day 30
|
Overall Dryness Measured With Visual Analog Scale (VAS)
Time Frame: Day 30
|
The participant rated overall dryness on a 100-millimeter analog scale by marking a line that best describes how dry their eyes feel (0=not at all dry, 100=very dry).
Both eyes were rated together as a single, retrospective evaluation of the previous 3 days of wear.
|
Day 30
|
Average Exposure Speed
Time Frame: Day 30
|
Exposure speed (rate of increase in exposed lens surface % (areas not protected by tear film) after the first tear film break and before the second blink) was measured with a diffuse illumination source (Tearscope) and videotography.
Higher speeds indicate worse tear film dynamics.
One eye (study eye) contributed to the mean.
|
Day 30
|
Minimum Protected Area
Time Frame: Day 30
|
Minimum protected area (i.e., minimum area of the lens (%) covered by the tear film during the interblink period) was measured using a diffuse illumination source (Tearscope) and videotography.
A higher value indicates a larger area of the tearfilm spread evenly over the lens (i.e., less area of tear film breakage).
One eye (study eye) contributed to the mean.
|
Day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
October 2, 2012
First Submitted That Met QC Criteria
October 2, 2012
First Posted (Estimate)
October 4, 2012
Study Record Updates
Last Update Posted (Estimate)
December 8, 2014
Last Update Submitted That Met QC Criteria
December 3, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M-12-043 / ID11-59
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractive Error
-
Alcon ResearchCompletedRefractive Error - Myopia Severe | Refractive Error - Myopia SimpleUnited States, Ireland, Singapore
-
Vision Service PlanCompletedRefractive Error - Myopia BilateralUnited States
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Vision Service PlanCompletedRefractive Error - Myopia BilateralUnited States
-
Wang HongxiaTianjin Eye HospitalCompletedRefractive Error - Myopia AxialChina
-
Tianjin Eye HospitalRecruitingMyopia; Refractive ErrorChina
-
Abbott Medical OpticsCompletedStable Myopic Refractive Error, With or Without AstigmatismUnited States
-
KK Women's and Children's HospitalWithdrawnRefractive Error - Myopia
-
Alcon ResearchCompletedRefractive ErrorsUnited States
-
Alcon ResearchCompletedRefractive ErrorsUnited States
Clinical Trials on Lotrafilcon B contact lenses
-
Alcon ResearchCompleted
-
Alcon ResearchCompletedRefractive Error | Presbyopia | Hyperopia
-
Alcon ResearchEnrolling by invitation
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Alcon ResearchCompletedAstigmatism | Myopia